Summary
[U.S. Drug Administration: Antibody testing has limited effectiveness in detecting Omi Kiron strain]The US Food and Drug Administration (FDA) warned on December 28 that antibody testing is useful in detecting the new crown mutant virus Omi Kiron strain. Or not very effective. The announcement issued by the US Drug Administration showed that early data showed that antibody testing could indeed detect that the patient was infected with the Omi Keron strain. But compared with nucleic acid detection, antibody detection is usually less sensitive. The U.S. Food and Drug Administration also made a recommendation that “people with symptoms of new coronary pneumonia or close contacts of patients with new coronary pneumonia should undergo follow-up nucleic acid testing, even if their antibody test results are negative.”
The U.S. Food and Drug Administration (FDA) warned on December 28 that antibody testing may not be effective in detecting the Omi Keron strain of the new coronavirus mutant.Issued by the FDAannouncementShow that early data shows that antibody testing can indeed detect that the patient is infected with the Omi Keron strain. But compared with nucleic acid detection, antibody detection is usually less sensitive. The U.S. Food and Drug Administration also made a recommendation that “people with symptoms of new coronary pneumonia or close contacts of patients with new coronary pneumonia should undergo follow-up nucleic acid testing, even if their antibody test results are negative.”
(Article source: Financial Association Press)
.